魚躍醫療(002223.SZ):擬參設南京盛宇黑科新智造創業投資合夥企業
格隆匯6月26日丨魚躍醫療(002223.SZ)公佈,公司擬與上海盛宇股權投資基金管理有限公司(簡稱“盛宇投資”)、丹陽盛宇高鑫股權投資合夥企業(有限合夥)(簡稱“盛宇高鑫”)、上海鋶晟投資中心(有限合夥)(簡稱“鋶晟投資”)、江蘇中盈投資管理有限公司(簡稱“中盈投資”)、上海松江創業投資管理有限公司(簡稱“松江創投”)等參與方共同投資設立南京盛宇黑科新智造創業投資合夥企業(有限合夥)(暫定名,以企業登記機關最終核准登記的名稱為準,簡稱“合夥企業”或“基金”),基金的普通合夥人及基金管理人為盛宇投資(以下簡稱“本次投資”)。基金規模為人民幣3億元,其中,公司計劃以自有資金出資不超過人民幣1億元。基金投資方向以醫療器械產業鏈為核心,佈局生物技術與生命科學上游,探索創新診療技術等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.